2023
Community health workers can be trained to identify patients eligible for tuberculosis preventive therapy, but encounter barriers to programme implementation in KwaZulu-Natal, South Africa
Norton S, Moll A, Madi J, Nkomo N, Brooks R, Andrews L, Shenoi S. Community health workers can be trained to identify patients eligible for tuberculosis preventive therapy, but encounter barriers to programme implementation in KwaZulu-Natal, South Africa. African Journal Of AIDS Research 2023, 22: 131-135. PMID: 37337826, DOI: 10.2989/16085906.2023.2213213.Peer-Reviewed Original ResearchConceptsTuberculosis preventive therapyCommunity health workersLargest HIV epidemicCause of deathNon-communicable diseasesHealth workersPreventive therapyRural resource-limited settingsHigh TB incidence ratesFurther implementation researchTB incidence rateRate of referralResource-limited settingsMedian ageTreatment initiationHIV epidemicIncidence rateRural South AfricaHIVInfectious diseasesTuberculosisImplementation researchScreening resultsDiseasePatients
2015
A Study of the Knowledge and Beliefs Held by Patients Infected With HIV and Their HIV Healthcare Providers Regarding Single-Tablet Regimens (STR). (KNABSTR Study)
Frank C, Kyriakides T, Omar A, Friedland G, Andrews L, Melbourne K, Kozal M. A Study of the Knowledge and Beliefs Held by Patients Infected With HIV and Their HIV Healthcare Providers Regarding Single-Tablet Regimens (STR). (KNABSTR Study). Open Forum Infectious Diseases 2015, 2: 1082. DOI: 10.1093/ofid/ofv133.795.Peer-Reviewed Original Research
2013
Pharmacokinetic Interactions between Buprenorphine/Naloxone and Raltegravir in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment
Bruce R, Moody DE, Chodkowski D, Andrews L, Fang WB, Morrison J, Parsons TL, Friedland GH. Pharmacokinetic Interactions between Buprenorphine/Naloxone and Raltegravir in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment. The American Journal Of Drug And Alcohol Abuse 2013, 39: 80-85. PMID: 23421567, DOI: 10.3109/00952990.2013.764885.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxoneHuman immuno-deficiency virusBuprenorphine/Buprenorphine/naloxone treatmentAddition of raltegravirOpioid-dependence therapiesHIV-seronegative subjectsEffect of raltegravirOpioid withdrawalNaloxone treatmentPharmacokinetic interactionsNaloxone concentrationsHistorical controlsPharmacodynamic parametersPharmacodynamic studiesBaseline valuesRaltegravirNaloxoneBuprenorphineSignificant differencesTherapySubjectsPrimary metabolitesSteady-state evaluationPatients
2002
The Pharmacokinetics of Methadone Following Co‐Administration with a Lamivudine/Zidovudine Combination Tablet in Opiate‐Dependent Subjects
Rainey PM, Friedland GH, Snidow JW, McCance‐Katz E, Mitchell SM, Andrews L, Lane B, Jatlow P. The Pharmacokinetics of Methadone Following Co‐Administration with a Lamivudine/Zidovudine Combination Tablet in Opiate‐Dependent Subjects. American Journal On Addictions 2002, 11: 66-74. PMID: 11876585, DOI: 10.1080/10550490252801657.Peer-Reviewed Original ResearchConceptsSerum concentrationsCombination tabletSerum concentration-time curveMethadone dose changesMethadone serum concentrationsMaximum serum concentrationOpiate-dependent subjectsConcentration-time curveVolume of distributionCombination pharmacotherapyMethadone pharmacokineticsTerminal eliminationCo-administrationDose changesMean areaSignificant differencesPharmacokineticsSubjectsSubject studyHIVPharmacotherapyPatientsAdministration